Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | CRHBP | P24387 | 1/20 | 0.53 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.52 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL620234 | 0.86 | RAB9A (0.53) | CHRNB2CHRNA4RAB9AMCHR2MCHR1 | |
| SCHEMBL5071539 | 0.83 | FFAR1 (0.53) | CHRNB2CHRNA4ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL618658 | 0.80 | HTT (0.81) | ALDH1A1SMN1; SMN2L3MBTL1FFAR1KDM4E | |
| SCHEMBL621388 | 0.80 | RAF1 (0.57) | ALDH1A1FFAR1KDM4ECRHBPCRHR2 | |
| SCHEMBL11570143 | 0.80 | FFAR1 (0.67) | ALDH1A1SMN1; SMN2FFAR1KDM4ECRHBP | |
| SCHEMBL6014110 | 0.77 | MCHR1 (0.66) | KMT2AMCHR2MCHR1 | |
| SCHEMBL618180 | 0.77 | CYP2C19 (0.66) | ALDH1A1SMN1; SMN2L3MBTL1FFAR1KDM4E | |
| SCHEMBL17918744 | 0.76 | HPGD (0.59) | RAB9ACHRM3 | |
| SCHEMBL177676 | 0.76 | FFAR1 (0.71) | ALDH1A1SMN1; SMN2FFAR1KDM4ECRHBP | |
| SCHEMBL668647 | 0.76 | FFAR1 (0.71) | ALDH1A1SMN1; SMN2FFAR1KDM4ECRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8841330-B2 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120142742-A1 | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHERCARE LLC (US) | 2012-06-07 | — | — | US | disclosed |
| EP-2298311-B1 | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2012-05-09 | — | — | EP | disclosed |
| US-8124630-B2 | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2012-02-28 | — | — | US | disclosed |
| US-20120040986-A1 | OMEGA CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | RIEDL BERND (DE) | 2012-02-16 | — | — | US | disclosed |
| EP-1158985-B1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2011-12-28 | — | — | EP | disclosed |
| US-7928239-B2 | Anticarcinogenic agents | BAYER HEALTHCARE LLC (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2298311-A1 | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors | Bayer Healthcare Llc (US) | 2011-03-23 | — | — | EP | disclosed |
| US-7897623-B2 | FDA Orange book listed patent for sorafenib tosylate; tablets | BAYER HEALTHCARE LLC (US) | 2011-03-01 | — | — | US | disclosed |
| US-20030139605-A1 | Method and/or process for preparing omega-carboxyaryl substituted diphenyl ureas as raf kinas inhibitors | BAYER HEALTHCARE LLC | 2003-07-24 | — | — | US | disclosed |
| US-20030105091-A1 | Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors | BAYER HEALTHCARE LLC | 2003-06-05 | — | — | US | disclosed |
| US-20020165394-A1 | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas | BAYER CORPORATION | 2002-11-07 | — | — | US | disclosed |
| US-20020137774-A1 | Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER CORPORATION | 2002-09-26 | — | — | US | disclosed |
| CN-1341098-A | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER AG (US) | 2002-03-20 | — | — | CN | disclosed |
| US-20010034447-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-25 | — | — | US | disclosed |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-04 | — | — | US | disclosed |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-23 | — | — | US | disclosed |
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | disclosed |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | CHRNB2 4704/4885CHRNA4 4818/4885ALDH1A1 1431/4885 |
| US-20020165394-A1 | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas | BRAF, RAF1, ARAF | CHRNB2 4618/4885CHRNA4 4591/4885ALDH1A1 2284/4885 |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, ARAF, RAF1 | CHRNB2 4683/4885CHRNA4 4772/4885ALDH1A1 1887/4885 |
| US-20020137774-A1 | Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, NRAS | CHRNB2 4826/4885CHRNA4 4871/4885ALDH1A1 1469/4885 |
| US-20010034447-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | CHRNB2 4710/4885CHRNA4 4810/4885ALDH1A1 1392/4885 |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | CHRNB2 4710/4885CHRNA4 4810/4885ALDH1A1 1392/4885 |
| US-20030139605-A1 | Method and/or process for preparing omega-carboxyaryl substituted diphenyl ureas as raf kinas inhibitors | RAF1, BRAF, ARAF | CHRNB2 4337/4885CHRNA4 4762/4885ALDH1A1 436/4885 |
| US-20030105091-A1 | Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors | MAPK1, MAPK8, MAPK3 | CHRNB2 4264/4885CHRNA4 4649/4885ALDH1A1 1329/4885 |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | CHRNB2 4618/4885CHRNA4 4754/4885ALDH1A1 1800/4885 |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BRAF, NRAS, ARAF | CHRNB2 4662/4885CHRNA4 4797/4885ALDH1A1 1474/4885 |
| US-20120040986-A1 | OMEGA CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, NRAS, RAF1 | CHRNB2 4729/4885CHRNA4 4828/4885ALDH1A1 1508/4885 |
| US-20120142742-A1 | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | CHRNB2 4710/4885CHRNA4 4810/4885ALDH1A1 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.